114468-05-2

Usage

Uses

Used in Pharmaceutical Industry:
Pyridine, 3-bromo-4-(difluoromethyl)(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, Pyridine, 3-bromo-4-(difluoromethyl)(9CI) serves as an essential intermediate for the production of various agrochemicals, including pesticides and herbicides. Its presence in these compounds contributes to their effectiveness in controlling pests and weeds.
Used in Organic Synthesis:
Pyridine, 3-bromo-4-(difluoromethyl)(9CI) is utilized in organic synthesis for the preparation of a wide range of organic compounds. Its reactivity allows for various chemical reactions, enabling the formation of diverse molecules with potential applications in different fields.
Used in Research:
Pyridine, 3-bromo-4-(difluoromethyl)(9CI) is also employed in research settings, where it is used to study the properties and behavior of pyridine derivatives. Researchers use Pyridine, 3-bromo-4-(difluoromethyl)(9CI) to explore its potential applications and to develop new methods for its synthesis and modification.

Upstream product

• 82878-62-4 4-(difluoromethyl)pyridine 
• 872-85-5 pyridine-4-carbaldehyde 
• 70201-43-3 3-bromo-pyridine-4-carbaldehyde 

Relevant academic research and scientific papers

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

NAPHTHYRIDINES AS INHIBITORS OF HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.

SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS

Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4 and R5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.

Syntheses of New Aromatic Compounds with Fluorinated Side Chains and their Chemical Reactivity

The syntheses of a wide range of aromatic compounds of the type p-Y-C6H4CF2X(4-13) are described, and the chemical behavior of these compounds as a function of substituent Y is investigated .Analogously the pyridine derivatives 15, 17, and 18 were synthesized and characterized.From a correlation of the 19F-NMR data of these compounds with the Hammett constant of Y, participation of C-F ?-back-donation is seen as the cause for an observed shift of the 19F signals to lower field.